A naukri.com initiative
Bioengineer
1w
263
Image Credit: Bioengineer
Advances in Modern Radiotherapy for Lung Cancer
- A meta-analysis evaluates low linear energy transfer (LET) radiation therapies like high-dose-rate (HDR) brachytherapy, stereotactic body radiotherapy (SBRT), and hypofractionated proton therapy for locally advanced non-small cell lung cancer (LA-NSCLC).
- HDR brachytherapy shows superior overall survival (OS) outcomes compared to SBRT and proton therapy, with a 68% two-year OS rate and median OS up to 38 months.
- In terms of local tumor control (LC), HDR brachytherapy demonstrates an 87.1% two-year LC rate, potentially surpassing SBRT and proton therapy.
- Achieving a biologically effective dose (BED₁₀) of 78 Gy or higher correlates with improved survival rates of up to 62% at two years.
- HDR brachytherapy exhibits low acute toxicity rates of 0-10% and minimal late toxicities above grade 3, contrasting with SBRT and proton therapy.
- Hypofractionated proton therapy, though not as efficacious as HDR brachytherapy in the study, shows promise for future enhancements in tumor control.
- The integration of modern radiotherapy with chemotherapy and immunotherapy can potentially enhance treatment outcomes for LA-NSCLC patients.
- The study underscores the importance of comprehensive evaluations in refining treatment strategies, particularly in areas where personalized care decisions are critical.
- The research positions HDR brachytherapy as a frontline option for LA-NSCLC patients not suitable for surgery due to its survival benefits and low toxicity profiles.
- Further prospective trials are recommended to validate and expand upon the study's findings, emphasizing the need for continuous refinement and integration of evolving therapies.
- Overall, the meta-analysis paves the way for more effective and targeted radiotherapy regimens in LA-NSCLC, offering hope for improved patient outcomes and prognosis.
Read Full Article
15 Likes
For uninterrupted reading, download the app